CD274 and non-small cell lung carcinoma: ,11 Another randomized trial comparing durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic NSCLC refractory to previous PD-L1 therapy was terminated owing to futility in an interim analysis.12